Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice

Cancer Gene Therapy volume 15, pages 108–114 (2008)Cite this article

Abstract

A recently developed, adaptive constant-current electroporation technique was used to immunize mice with an intramuscular injection of plasmid coding for the extracellular and transmembrane domains of the product of the rat neu664V-E oncogene protein. In wild-type BALB/c mice, plasmid electroporation at lower current settings elicits higher antibody titers, a strong cytotoxic response and completely protects all mice vaccinated with 10, 25 and 50 μg of plasmid against a lethal challenge of rat neu+ carcinoma cells. BALB/c mice transgenic for the transforming rat neu664V−E (ErbB-2, Her-2/neu) oncogene (BALB-neuT664V−E) develop an invasive mammary gland carcinoma by 20 weeks of age. Remarkably, when transgenic BALB-neuT664V−E mice were vaccinated at a 10- week interval with 50 μg of plasmid with 0.2 A electroporation, mice remained tumor free for more than a year. A single administration of plasmid associated with electroporation was enough to markedly delay carcinogenesis progression in mice with multiple microscopic invasive carcinomas, and keep about 50% of mice tumor free at one year of age. Thus, vaccination using a clinically relevant dose of plasmid encoding the extracellular and transmembrane domains of the neu oncogene delivered by electroporation prevents long-term tumor formation. These improvements in the efficacy of this cancer vaccine regimen vastly increase its chances for clinical success.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Brown PA, Davis WC, Draghia-Akli R . Immune enhancing effects of growth hormone releasing hormone delivered by plasmid injection and electroporation. Mol Ther 2004; 10: 644–651.

    Article  CAS  Google Scholar 

  2. Draghia-Akli R, Fiorotto ML . A new plasmid-mediated approach to supplement somatotropin production in pigs. J Anim Sci 2004; 82: E264–E269.

    PubMed  Google Scholar 

  3. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R . Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6: 243–273.

    Article  CAS  Google Scholar 

  4. Khan AS, Pope MA, Draghia-Akli R . Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol 2005; 24: 810–818.

    Article  CAS  Google Scholar 

  5. Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P . Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 2004; 15: 189–201.

    Article  CAS  Google Scholar 

  6. Fattori E, Cappelletti M, Zampaglione I, Mennuni C, Calvaruso F, Arcuri M et al. Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 2005; 7: 228–236.

    Article  CAS  Google Scholar 

  7. Lollini PL, Cavallo F, Nanni P, Forni G . Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 204–216.

    Article  CAS  Google Scholar 

  8. Stan R, Wolchok JD, Cohen AD . DNA vaccines against cancer. Hematol Oncol Clin North Am 2006; 20: 613–636.

    Article  Google Scholar 

  9. Gothelf A, Mir LM, Gehl J . Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371–387.

    Article  CAS  Google Scholar 

  10. Heller LC, Heller R . In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17: 890–897.

    Article  CAS  Google Scholar 

  11. Di CE, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 1999; 79: 1261–1269.

    Google Scholar 

  12. Lollini PL, Nicoletti G, Landuzzi L, De GC, Rossi I, Di CE et al. Downregulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int J Cancer 1998; 77: 937–941.

    Article  CAS  Google Scholar 

  13. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003; 170: 4273–4280.

    Article  CAS  Google Scholar 

  14. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di CE et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64: 2858–2864.

    Article  CAS  Google Scholar 

  15. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133–5142.

    Article  CAS  Google Scholar 

  16. Ritchie DS, Hermans IF, Lumsden JM, Scanga CB, Roberts JM, Yang J et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods 2000; 246: 109–117.

    Article  CAS  Google Scholar 

  17. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336–1343.

    CAS  Google Scholar 

  18. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P et al. Immunosurveillance of Erb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66: 7734–7740.

    Article  CAS  Google Scholar 

  19. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006; 177: 7626–7633.

    Article  CAS  Google Scholar 

  20. Pannellini T, Forni G, Musiani P . Immunobiology of her-2/neu transgenic mice. Breast Dis 2004; 20: 33–42.

    Article  Google Scholar 

  21. Babiuk S, Baca-Estrada M, Foldvari M, Storms M, Rabussay D, Widera G et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20: 3399.

    Article  CAS  Google Scholar 

  22. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Therapy 2004; 11: 711–721.

    Article  CAS  Google Scholar 

  23. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ . Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115–121.

    Article  Google Scholar 

  24. Spadaro M, Ambrosino E, Iezzi M, Di CE, Sacchetti P, Curcio C et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005; 11: 1941–1952.

    Article  CAS  Google Scholar 

  25. Heller R, Gilbert R, Jaroszeski MJ . Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Adv Drug Deliv Rev 1997; 26: 185–197.

    Article  CAS  Google Scholar 

  26. Heller LC, Coppola D . Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Therapy 2002; 9: 1321–1325.

    Article  CAS  Google Scholar 

  27. Babiuk S, Baca-Estrada ME, Foldvari M, Middleton DM, Rabussay D, Widera G et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004; 110: 1–10.

    Article  CAS  Google Scholar 

  28. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336–1343.

    CAS  Google Scholar 

  29. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P . Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105–115.

    Article  CAS  Google Scholar 

  30. Melani C, Chiodoni C, Forni G, Colombo MP . Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102: 2138–2145.

    Article  CAS  Google Scholar 

  31. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ . Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175–213.

    Article  CAS  Google Scholar 

  32. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174: 4228–4236.

    Article  CAS  Google Scholar 

  33. Hebel H, Attra H, Khan A, Draghia-Akli R . Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine 2006; 24: 4607–4614.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Italian Association for Cancer Research, the Italian Ministries for the Universities and Health, University of Torino and Compagnia di San Paolo, Turin.

Author information

Authors and Affiliations

  1. Department of Clinical and Biological Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy

    C Curcio, M Spadaro, E Quaglino, F Cavallo & G Forni

  2. Immune Therapeutics Division, VGX Pharmaceuticals, The Woodlands, TX, USA

    A S Khan & R Draghia-Akli

  3. Department of Molecular, Cellular and Animal Biology, University of Camerino, Camerino, Italy

    A Amici

Authors
  1. C Curcio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A S Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Amici
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Spadaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Quaglino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Cavallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Forni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Draghia-Akli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Draghia-Akli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curcio, C., Khan, A., Amici, A. et al. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 15, 108–114 (2008). https://doi.org/10.1038/sj.cgt.7701106

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7701106

Keywords

This article is cited by

Search

Advanced search

Quick links